On this page
Abaloparatide Quick Reference (3 mg Vial)
- Vial contents
- 3 mg Abaloparatide
- Final volume
- 3 mL
- Concentration
- 1 mg/mL
- One U-100 unit
- 10 mcg in 0.01 mL
Abaloparatide Dosage Chart
Dosing & Reconstitution Guide
One-Vial Calculation Using the Human-Study Daily Amount
One-Vial Calculation Using the Human-Study Daily Amount
| Research Period | Amount per Administration | U-100 Units (mL) |
|---|---|---|
| 37 daily administrations (one-vial arithmetic) | 80 mcg | 8 units (0.08 mL) |
Frequency: Once daily in the cited ACTIVE, ATOM, and ACTIVE-J trials.[2][4][5]
Research reference only: The 80 mcg amount and once-daily frequency come from human trials and the approved label. The 37-administration period is a one-vial arithmetic result, not a clinical trial duration or a recommendation. The approved pen and a 3 mg research vial are not formulation equivalents.
Reconstitution Steps
- Clean the vial stopper and diluent stopper with alcohol; allow both to dry.
- Draw exactly 3.0 mL of bacteriostatic water with a new sterile syringe, then inject it slowly down the inside wall of the vial.
- Gently swirl or roll until dissolved. Do not shake.
- Label the vial with compound, concentration, and preparation date. Store it according to verified product-specific instructions.
Supplies Needed
This supply calculation covers the 37 complete 80 mcg arithmetic amounts contained in one 3 mg vial. It does not define a treatment course or post-reconstitution use-by period.
- Peptide Vials (Abaloparatide, 3 mg each):
- One-vial calculation: 1 vial
- Insulin Syringes (U-100):
- 37 calculated administrations: 37 syringes
- Bacteriostatic Water (10 mL bottle):
- 1 vial at 3.0 mL: 3.0 mL total
- Alcohol Swabs:
- 37 calculated administrations at 2 swabs each: 74 swabs
Sharps safety: Place used needles and syringes immediately in an approved sharps container.
PeptideDosages has no affiliation with Pure Lab Peptides and receives no commission from these Pure Lab links. Supplier pages are not scientific evidence or proof of suitability for human use.
Abaloparatide Vial and Research Context
- Reconstitute: Add 3.0 mL bacteriostatic water for a calculated concentration of 1 mg/mL.
- Vial contents: 3 mg Abaloparatide.
- U-100 conversion: At 1 mg/mL, 1 unit = 0.01 mL = 10 mcg.
- Storage: Follow the exact product label and laboratory stability instructions. Do not infer a universal use-by period from vial strength alone.
Abaloparatide has a direct human dosing evidence base, but clinical studies used controlled drug formulations. The 3 mg vial calculation below does not establish interchangeability, product quality, or a new treatment recommendation.[1][2]
Abaloparatide Dosage Evidence
Abaloparatide is a parathyroid hormone-related protein analog and selective activator of the parathyroid hormone type 1 receptor.[2][16] The 80 mcg daily amount has been evaluated in multiple randomized human trials, including ACTIVE, ATOM, and ACTIVE-J.[2][4][5] Bone histology and histomorphometry were also evaluated in an ACTIVE substudy.[7] The approved TYMLOS product is a 3120 mcg/1.56 mL multidose pen, not a 3 mg lyophilized vial.[1] This page therefore separates clinical-study dosing evidence from research-vial arithmetic.
Early dose-ranging work evaluated 20, 40, and 80 mcg daily, with larger bone-mineral-density changes at 40 and 80 mcg than placebo.[3] Later studies used 80 mcg daily for 12 to 18 months in different osteoporosis populations.[2][4][5] A separate randomized study also examined 40 and 80 mcg daily.[6]
ACTIVE reported fracture and bone-density outcomes in postmenopausal women, while ATOM evaluated men and ACTIVE-J evaluated Japanese participants at high fracture risk.[2][4][5] These population-specific findings do not validate a third-party research vial or establish interchangeability with the FDA-approved pen.
3 mg Vial Calculation Notes
- 3 mg divided by 3.0 mL equals 1 mg/mL.
- At 1 mg/mL, 0.01 mL equals 10 mcg.
- 80 mcg divided by 10 mcg per unit equals 8 U-100 units (0.08 mL).
- A 3 mg vial contains 37 complete 80 mcg calculated amounts with 40 mcg remaining. This yield is arithmetic only and does not establish a stability window.
Fracture, Bone Density, and Microarchitecture Findings
ACTIVE and its extension program examined vertebral and nonvertebral fractures, bone density, and sequential treatment outcomes.[2][8][9] Additional analyses examined baseline fracture risk, trabecular bone score, age-related subgroups, forearm outcomes, and trabecular microarchitecture.[10][11][12][13][14][15]
These studies provide a substantial human evidence base for the approved drug formulation. They do not establish the purity, sterility, excipients, pharmacokinetics, or clinical equivalence of a research vial.
Safety and Formulation Limits
The FDA label lists warnings, contraindications, adverse reactions, and pen-specific storage instructions.[1] ACTIVE reported prespecified safety outcomes, and ATOM reported injection-site reaction, dizziness, nasopharyngitis, arthralgia, bronchitis, hypertension, and headache among common treatment-emergent events.[2][4] Product-specific prescribing and monitoring decisions require a licensed clinician.
References
- 1U.S. FDA, TYMLOS prescribing information (2026) – Official product labeling for the approved abaloparatide injection pen, including 80 mcg once-daily dosing and formulation-specific handling. The pen is not interchangeable with a lyophilized research vial.
- 2Miller et al., 2016, PMID 27533157 – ACTIVE randomized trial of abaloparatide 80 mcg subcutaneously once daily for 18 months in postmenopausal women with osteoporosis.
- 3Leder et al., 2015, PMID 25393645 – Randomized dose-ranging trial comparing 20, 40, and 80 mcg daily subcutaneous abaloparatide over 24 weeks.
- 4Czerwinski et al., 2022, PMID 36190391 – ATOM randomized trial of 80 mcg daily subcutaneous abaloparatide for 12 months in men with osteoporosis.
- 5Matsumoto et al., 2022, PMID 35977548 – ACTIVE-J randomized trial of 80 mcg daily for 78 weeks in Japanese participants with osteoporosis at high fracture risk.
- 6Miller et al., 2023, PMID 37505256 – Randomized study examining 40 and 80 mcg daily abaloparatide in postmenopausal women.
- 7Moreira et al., 2017, PMID 27826127 – Bone histology and histomorphometry analysis from ACTIVE participants receiving 80 mcg daily.
- 8Bone et al., 2018, PMID 29931216 – ACTIVExtend analysis of sequential abaloparatide followed by alendronate.
- 9Cosman et al., 2019, PMID 31674644 – Post hoc comparison of vertebral fracture outcomes in ACTIVE and ACTIVExtend.
- 10McCloskey et al., 2019, PMID 30719589 – Analysis of fracture outcomes across baseline FRAX risk in ACTIVE.
- 11Bilezikian et al., 2023, PMID 36588166 – Trabecular bone score analysis in participants receiving abaloparatide.
- 12McClung et al., 2018, PMID 29462094 – ACTIVE subgroup analysis in women aged 80 years or older.
- 13Miller et al., 2020, PMID 32513495 – Subgroup analysis of younger postmenopausal women enrolled in ACTIVE.
- 14Watts et al., 2019, PMID 30899994 – Forearm bone-density and wrist-fracture outcomes in ACTIVE.
- 15Doyle et al., 2018, PMID 29167971 – Imaging analysis of trabecular microarchitecture across abaloparatide dose groups.
- 16Leder et al., 2017, PMID 28624872 – Peer-reviewed overview of abaloparatide pharmacology and initial approval.